Business
DECN to Immediately Take Control of Two Market Ready, FDA Cleared, Glucose Monitoring Systems to Augment Its Primary Marketplace Positions
DECN to Immediately Take Control of Two Market Ready, FDA Cleared, Glucose Monitoring Systems to Augment Its Primary Marketplace Positions.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Company Adding A Low End System For Sale On Amazon, Walmart & Other Sites, While Second System With A Multi-Patient Monitor Is Perfect For Nursing Homes & ClinicsLOS ANGELES, CA / ACCESSWIRE / December 10, 2019 / Decision Diagnostics Corp. (OTCPINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.DECN announces today that we have decided to import and take control of two products that will round out our product lines in anticipation of our highly anticipated GenUltimate TBG products. The first product, which we named GenAccord! Is a practical FDA cleared lower end product that will be sold on amazon, Walmart and other e-commerce sites. We also anticipate private label and wholesale market to develop. GenAccord! will have a private label equivalent to be sold under the label Advant!Keith Berman, CEO of DECN commented, "We have been in discussions with both a Korean and a Taiwanese manufacturer, each long standing and viable companies, for the import of a low end product already cleared by the FDA for U.S. sales and approved for CE Mark for European sales. Carrying the DECN brand enhances these products, which are immediately ready for sale in 1Q 2020. No investment in further development is required, which was a prerequisite."In addition to the lower market end system GenAccord!, the company is also going to add a second system cleared by the FDA for multi-patient use. Multi-patient meters are required where the setting is a nursing home, clinic or health fair. This system will be di...